Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.
Barbara McAneny, MD
Advertisement
Articles by Barbara McAneny, MD
Advertisement
Latest Updated Articles
How Oral Targeted Therapies and IV Immunotherapies Disrupted Community Practice FinancingPublished: April 27th 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
